BR112016011567A2 - receptores de célula t humana de alta afinidade geneticamente modificados. - Google Patents

receptores de célula t humana de alta afinidade geneticamente modificados.

Info

Publication number
BR112016011567A2
BR112016011567A2 BR112016011567A BR112016011567A BR112016011567A2 BR 112016011567 A2 BR112016011567 A2 BR 112016011567A2 BR 112016011567 A BR112016011567 A BR 112016011567A BR 112016011567 A BR112016011567 A BR 112016011567A BR 112016011567 A2 BR112016011567 A2 BR 112016011567A2
Authority
BR
Brazil
Prior art keywords
genetically modified
high affinity
cell receptors
modified high
affinity human
Prior art date
Application number
BR112016011567A
Other languages
English (en)
Inventor
t harris Daniel
M Kranz David
D Greenberg Philip
N Smith Sheena
M Schmitt Thomas
Original Assignee
Hutchinson Fred Cancer Res
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res, Univ Illinois filed Critical Hutchinson Fred Cancer Res
Publication of BR112016011567A2 publication Critical patent/BR112016011567A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112016011567A 2013-11-22 2014-11-21 receptores de célula t humana de alta afinidade geneticamente modificados. BR112016011567A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
PCT/US2014/066903 WO2015077615A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (1)

Publication Number Publication Date
BR112016011567A2 true BR112016011567A2 (pt) 2017-10-24

Family

ID=53180203

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011567A BR112016011567A2 (pt) 2013-11-22 2014-11-21 receptores de célula t humana de alta afinidade geneticamente modificados.

Country Status (20)

Country Link
US (4) US10023625B2 (pt)
EP (2) EP3071594A4 (pt)
JP (4) JP6476182B2 (pt)
KR (2) KR20160085345A (pt)
CN (2) CN105899530B (pt)
AU (4) AU2014352834B2 (pt)
BR (1) BR112016011567A2 (pt)
CA (2) CA2930847A1 (pt)
DK (1) DK3071593T3 (pt)
ES (1) ES2729406T3 (pt)
IL (2) IL245467B (pt)
MX (3) MX371202B (pt)
PL (1) PL3071593T3 (pt)
PT (1) PT3071593T (pt)
RU (2) RU2729383C2 (pt)
SA (1) SA516371174B1 (pt)
SG (2) SG10201804330YA (pt)
TR (1) TR201908404T4 (pt)
WO (2) WO2015077607A1 (pt)
ZA (2) ZA201603116B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3834836A1 (en) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and uses thereof
WO2013106834A2 (en) 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
HUE052541T2 (hu) 2013-01-15 2021-05-28 Memorial Sloan Kettering Cancer Center Immunogén WT-1 peptidek és eljárások azok alkalmazására
KR20160085345A (ko) * 2013-11-22 2016-07-15 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
EP3352798A1 (en) * 2015-09-22 2018-08-01 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
WO2017055635A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3394092A1 (en) 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3538113A4 (en) 2016-11-14 2020-08-19 Fred Hutchinson Cancer Research Center HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN SPECIFIC TCRs AND THEIR USES
CA3055983A1 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof
EP3615565A1 (en) * 2017-04-24 2020-03-04 Ospedale San Raffaele S.r.l. Tcr and peptides
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
WO2020023556A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
KR20220050176A (ko) * 2019-08-20 2022-04-22 프레드 헛친슨 켄서 리서치 센터 Wt-1에 특이적인 t-세포 면역요법
AU2021218412A1 (en) * 2020-02-12 2022-09-08 Abbvie Inc. Bispecific binding molecules
AU2021262547A1 (en) 2020-04-28 2022-11-10 Achilles Therapeutics Uk Limited T cell therapy
US20240210396A1 (en) 2021-04-09 2024-06-27 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
WO2022269250A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
CN117957012A (zh) * 2021-07-19 2024-04-30 得克萨斯州大学系统董事会 靶向fanci、rad51和pbk抗原的肽和经改造t细胞受体及使用方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
EP0486622B1 (en) 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
JP2002515243A (ja) 1998-05-19 2002-05-28 アヴィデックス リミテッド 多価ｔ細胞受容体複合体
DE69936927T2 (de) 1998-10-21 2008-05-15 Altor Bioscience Corp., Miramar Polyspezifische bindemoleküle und deren verwendung
US7329731B2 (en) * 2001-08-31 2008-02-12 Medigene Limited Soluble T cell receptor
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
WO2005114215A2 (en) 2004-05-19 2005-12-01 Avidex Ltd Method of improving t cell receptors
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
CA2743669C (en) * 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
EP2393833A1 (en) * 2009-02-09 2011-12-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2486049A1 (en) * 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
EP2598528A1 (en) * 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
CN105255834B (zh) 2010-09-20 2019-11-12 生物技术细胞和基因治疗公司 抗原特异性t细胞受体和t细胞表位
KR102276888B1 (ko) 2012-05-03 2021-07-14 프레드 헛친슨 켄서 리서치 센터 증강된 친화성 t　세포 수용체 및 이의 제조 방법
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
KR20160085345A (ko) 2013-11-22 2016-07-15 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1

Also Published As

Publication number Publication date
EP3071594A1 (en) 2016-09-28
JP6697386B2 (ja) 2020-05-20
ZA201603116B (en) 2018-12-19
DK3071593T3 (da) 2019-06-11
IL245468A0 (en) 2016-06-30
CA2930852A1 (en) 2015-05-28
EP3071593B1 (en) 2019-03-13
MX2016006625A (es) 2016-12-02
EP3071594A4 (en) 2017-05-03
PT3071593T (pt) 2019-06-27
JP2022023196A (ja) 2022-02-07
RU2016124179A (ru) 2017-12-27
CN105873945A (zh) 2016-08-17
SA516371174B1 (ar) 2019-04-14
IL245468B (en) 2020-10-29
IL245467A0 (en) 2016-06-30
JP6476182B2 (ja) 2019-02-27
RU2729383C2 (ru) 2020-08-06
AU2019272003B2 (en) 2021-05-06
US10023625B2 (en) 2018-07-17
EP3071593A4 (en) 2017-05-03
RU2016124163A (ru) 2017-12-27
CA2930852C (en) 2024-01-23
BR112016011583A2 (pt) 2017-09-26
TR201908404T4 (tr) 2019-07-22
CN105899530B (zh) 2020-05-08
ES2729406T3 (es) 2019-11-04
US10344075B2 (en) 2019-07-09
US20190055298A1 (en) 2019-02-21
AU2014352834B2 (en) 2019-08-29
KR20160085345A (ko) 2016-07-15
WO2015077607A1 (en) 2015-05-28
CA2930847A1 (en) 2015-05-28
JP2017501129A (ja) 2017-01-12
ZA201603169B (en) 2020-05-27
MX2021006932A (es) 2021-07-07
KR102415259B1 (ko) 2022-06-30
EP3071593A1 (en) 2016-09-28
CN105899530A (zh) 2016-08-24
US20220396606A1 (en) 2022-12-15
JP2020007374A (ja) 2020-01-16
AU2014352826A1 (en) 2016-05-26
PL3071593T3 (pl) 2019-11-29
JP2017501130A (ja) 2017-01-12
AU2021202274A1 (en) 2021-05-06
JP6970724B2 (ja) 2021-11-24
SG10201804335QA (en) 2018-06-28
AU2019272003A1 (en) 2019-12-19
US20160280756A1 (en) 2016-09-29
NZ719707A (en) 2020-09-25
RU2740648C2 (ru) 2021-01-19
MX371202B (es) 2020-01-22
AU2014352834A1 (en) 2016-05-26
US20160280755A1 (en) 2016-09-29
MX2016006620A (es) 2017-05-11
KR20160087866A (ko) 2016-07-22
NZ719720A (en) 2020-09-25
SG10201804330YA (en) 2018-07-30
WO2015077615A1 (en) 2015-05-28
IL245467B (en) 2020-04-30
AU2014352826B2 (en) 2019-08-01
CN105873945B (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
BR112016011567A2 (pt) receptores de célula t humana de alta afinidade geneticamente modificados.
DK3071223T3 (da) Cell
DK3336106T3 (da) Anti-fcrh5-antistoffer
DK3017520T3 (da) Solcelleanordning
LT3024468T (lt) T ląstelių receptoriai
DK3587448T3 (da) Heterodimere proteiner
DK2994528T3 (da) Organoider, der omfatter isolerede renale celler og anvendelser deraf
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
CL2015002750A1 (es) Anticuerpos humanos pac1
GB201314404D0 (en) T Cell Receptors
IL246572B (en) Examining an original application
FR3003076B1 (fr) Supercondensateur electrochimique
DK3234476T3 (da) Solfanger
IL244016A0 (en) Host cell modification with artificial endosymbionts
DK3021928T3 (da) Selvekspanderende kanyle
DK3068800T3 (da) FcRn-specifikke antistoffer
DK3087076T3 (da) Imidazopyrazinonderivater
DK3065774T3 (da) Anti-CCL17-antistoffer
GB201322430D0 (en) T cell receptors
FR3012417B1 (fr) Nacelle de turboreacteur
BR112016002552A2 (pt) rimel em gel
DK2988732T3 (da) Modificerede hydrogeler
DK3089990T3 (da) Forbedret proteinekspression
DK3089991T3 (da) Forbedret proteinekspression
TH1401007645A (th) เซลล์แสงอาทิตย์ (Solar Cells)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements